Driven
by the
Belief
that
One Purpose
23000+
people
We accelerate access
to affordable and
innovative medicines 45+
nationalities
because
400+
products
40+
countries
2
Our five
promises clarify
what we do,
Our Purpose Bringing Addressing
what we offer
guides our expensive medicine unmet and the
within reach patient needs commitments
commitment we make to our
to our 1 2 stakeholders.
Enabling and As we keep the
customers helping our
partners ensure
5 3 Helping interests of our
and our that our medicines
patients manage patients at the
4 disease better
are available center of all that
strategic
where needed
we do, our
choices
promises drive
Working with us to reach
partners to help higher levels of
them succeed
excellence.
Dr. Reddy’s at a glance 10/8/2020 3
As an integrated global pharmaceutical
enterprise, we operate through three
core business segments:
Pharmaceutical Global Generics Proprietary
Services & Active Products
Ingredients
Partner of Choice Access to affordable medicines Fulfilling unmet medical needs
Global leader in integrated Finished dosage businesses Developing differentiated
development, in distribution-driven formulations that present
manufacturing and unbranded as well as significantly enhanced
supply of APIs. detailing-driven branded benefits in terms of
markets. efficacy, ease of use,
Contract research, North America, Europe, India, and the resolution of
development China, Russia & CIS countries unmet patient needsy
and manufacturing are key markets in this
services. segment.
Dr. Reddy’s at a glance 10/8/2020 4
We have had significant success in highly regulated markets…
Revenue split by business Split of GG business by Geography
6%
14%
North America 37%
Emerging Markets 19%
India 17%
80% Europe 7%
Proprietary Products & Others PSAI Global Generics
Revenues for FY20 - $2.3 Bn
...with presence in all major regions of the
world 9
API
Manufacturing
Facilities
Commercial
Presence in 13
42
Formulations
Manufacturing
Facilities
Countries
9
ALGERIA COLOMBIA KAZAKHSTAN ROMANIA UK Global
AUSTRALIA FRANCE MALAYSIA RUSSIA UKRAINE R&D Centres
BANGLADESH GERMANY MALDIVES SINGAPORE US
1
BARBADOS GHANA MEXICO SOUTH AFRICA UZBEKISTAN
BELARUS GUATEMALA MOROCCO SPAIN VENEZUELA
BRAZIL INDIA MYANMAR SRI LANKA VIETNAM
Biologics
CANADA INDONESIA NEPAL THAILAND
Development
CHILE ITALY NEW ZEALAND TRINIDAD Centres
CHINA JAMAICA PERU TURKEY
We use science and technology
In FY2020
to provide affordable and
innovative medicines.
Our R&D Strengths 8 10 168
ANDAs DMFs New products launched
State-of-the-art R&D centers in India, U.K., U.S. & Netherlands in US including 4 re-launches
Over 1400+ research scientists working on various projects
Industry-leading chemistry skills First Indian-company- launched Para IV
• Niche product opportunities (Tacrolimus, product, Fluoxetine, in USA
Metoprolol succinate, Azacitadine, Divalproex Sodium ER)
Vertical integration
World’s first generic monoclonal antibody
• Integrated R&D
of Rituximab Reditux
• API manufacturing (9 facilities)
• Formulations manufacturing (13 facilities)
Several complex generics launched in USA
Early-mover advantage in biosimilars
with fewer than three competitors, e.g.,
Fondaparinux
• 6 biosimilar products being marketed
• Biologics development and manufacturing in India Dr. Reddy’s at a glance 10/8/2020 7
We strive to be the
first to launch
tough-to-make products
and differentiated
formulations
IP and technology-driven active ingredients
Complex generics and biologics
Differentiated formulations and novel products for
unmet needs
Dr. Reddy’s at a glance 10/8/2020 8
We are recognized for our strong
India’s Best corporate governance
Managed
Board
Our Board was named one of India’s best managed boards
by Mint and Aon Hewitt and by Economic Times and Hays in
their respective studies
We were declared Indian MNC of the year at the All India
Management Association (AIMA) Awards 2016.
In the Asian Centre for Corporate Governance &
Sustainability’s Leadership, Corporate Governance,
Sustainability & CSR Awards 2015, we were conferred with
the "Best Governed Company" award.
2001
Dr. Reddy’s becomes the first Asia Pacific pharmaceutical company,
besides Japan, to list on the New York Stock Exchange (NYSE).
Dr. Reddy’s at a glance 10/8/2020 9
Great Place Our people practices
to Work® across the markets we
operate in
We were ranked India’s Best Companies To
Work For among biotechnology and pharmaceutical
companies by Great Place to Work®, in 2017
Best Places to Work in 2017 in New Jersey
by NJBIZ
We were featured in the first Sector-Neutral
Bloomberg Gender-Equality Index in 2020. It
makes us the first pharmaceutical company
globally, and the only Indian company to make
it to the list!
Dr. Reddy’s at a glance 10/8/2020 10
A strong commitment to the community
School Improvement Program (SIP):
SIP aims at ensuring continuous quality education to students from less
privileged backgrounds. Through this program, Dr. Reddy’s has played an
important role in shaping the lives of over 1,00,000 students from 229
Government schools in Andhra Pradesh and Telangana.
Livelihood and Skilling:
Dr. Reddy’s GROW is a skilling initiative that helps unemployed youth from
marginalized sections and people with disabilities. The program has impacted
over 300,000 youth through placement and training. Also, over 16,000
farmers have been benefited through MITRA, a livelihood program that aims
at empowering and educating farmers.
Community Health Intervention Program (CHIP):
CHIP aims at improving access to primary healthcare for people in rural
communities, with a special focus on reducing the mortality rate of infants and
children. The program has impacted a population of over 2,00,000 in 155
villages. Support to non-profit organizations such as Naandi Foundation,
Roshni Trust.
Dr. Reddy’s at a glance 10/8/2020 11
Driving the 9 pillars of Started our sustainability
sustainable operations
efforts in 2004, which was a
pioneering effort back then
We have been able to fully integrate sustainability in our core
operations through well documented progress on our 9 pillars:
People
We became the first Indian
Safety pharmaceutical company, and
the only generic player globally
Quality to be included in the Dow Jones
Environment
Sustainability Index 2019 for
Emerging Markets. We also
Productivity received the prestigious Golden
Peacock Award for our efforts
Community
towards sustainability.
Availability
Continuous Improvement
Engineering Excellence
Dr. Reddy’s at a glance 10/8/2020 12
Our
Journey
“Charting out a course in
unknown waters and
learning along the way has
made the difference to us.”
- Satish Reddy, Chairman
Dr. Reddy’s at a glance 10/8/2020 13
Our journey has covered six phases
1984 1991
The birth of From
a dream molecules to
affordable
medicines
Scientist and entrepreneur, Dr. K. Anji Reddy establishes Having successfully made active ingredients accessible, Dr.
Dr. Reddy’s Laboratories with a vision of making medicines Reddy’s focuses on bringing the dosage forms themselves
accessible to the millions in India. within reach of millions of patients worldwide. In 1991, Omez,
Dr. Reddy’s brand of Omeprazole, goes on to become the
• The company begins by producing Methyldopa – a company’s first INR 1 Billion brand.
hypertension drug that was unavailable in India until 1985.
• The focus is now firmly on medicines, rather than the molecules
• By 1990, Dr. Reddy’s is the first Indian pharma company to that go into them.
export Norfloxacin and Ciprofloxacin to Europe and the Far
East. • Today, Omez is a market leader in eleven countries, and is the
No. 1 branded Omeprazole in the world.
Our journey has covered six phases
1995 2007
Expanding to Accelerating
reach patients access to
in other expensive
countries therapies
Realizing the importance of making innovative medicines Staying sharply focused on patient needs, Dr. Reddy’s focuses
more accessible the world over, Dr. Reddy’s creates world- on making expensive therapies against disease, affordable.
class capabilities, beginning with a finished dosage facility
in Hyderabad. • In 2007, Dr. Reddy’s launches the world’s first biosimilar
monoclonal antibody (mAb), Rituximab. The product makes
• It expands globally and enters highly regulated markets like treatment of cancers like Non-Hodgkin’s lymphoma, accessible
the USA. By 2000 Dr. Reddy’s becomes India’s third largest to millions of patients worldwide.
pharmaceutical company.
• In 2010, Dr. Reddy’s launches the first biosimilar darbepoetin
• In 2001 Dr. Reddy’s becomes the first Asia Pacific alfa in the world, and brings relief to millions of anaemia
pharmaceutical company, outside Japan, to list on the New patients.
York Stock Exchange.
Our journey has covered six phases
2010 2015
From Re-dedicating
medicines ourselves to
to health patient-
centricity
Taking a holistic view of patient needs, Dr. Reddy’s focuses Having built a diverse set of global businesses,
on creating and rolling out a number of programs to help Dr. Reddy’s unites all of them with a common purpose that’s
patients, doctors and caregivers better managing disease. simple and yet, powerful:
• Programs like Sparsh and Promius Promise™ go a long • We accelerate access to affordable and innovative medicines
way in helping patients get treatment and manage disease because Good Health Can’t Wait.
better.
• Our logo is an expression of Empathy and Dynamism which
helps keep patients at the centre of everything we do at Dr.
Reddy’s.
Our
Future
“We are impacting millions
of patients by empowering
our people to act with
agility and to do what is
tough and worthwhile.”
- G V Prasad, CEO
Dr. Reddy’s at a glance 10/8/2020 17
“The mission is to
improve the quality of life
and life expectancy itself.
This requires good
science. But for science
to be good, it has to
result in affordable
medicine.”
Dr. K. Anji Reddy
Founder, Dr. Reddy’s
CONTACT About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. is an integrated pharmaceutical company, committed
to providing affordable and innovative medicines for healthier lives. Through its three businesses -
Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s
offers a portfolio of products and services including APIs, custom pharmaceutical services, generics,
Investor relations Media relations biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal,
cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in
AMIT AGARWAL APARNA TEKURI markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and
Europe. For more information, log on to: www.drreddys.com
amita@drreddys.com aparnatekuri@drreddys.com Disclaimer: This presentation may include statements of future expectations and other forward-looking
statements that are based on the management’s current views and assumptions and involve known or
(Ph: +91-40-49002135) (Ph: +91-40- 49002446) unknown risks and uncertainties that could cause actual results, performance or events to differ
materially from those expressed or implied in such statements. In addition to statements which are
forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends",
"anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions
identify forward-looking statements. Actual results, performance or events may differ materially from
those in such statements due to without limitation, (i) general economic conditions such as
performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency
levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii)
changing levels of competition and general competitive factors, (iv) changes in laws and regulations
and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganisation
, including related integration issues.
The company assumes no obligation to update any information contained herein.
Registered Office:
Dr. Reddy’s Laboratories Ltd. 8-2-337 | Road No. 3, Banjara Hills,
Hyderabad - 500034, Telangana, India.
Tel: 91 40 4900 2900 | Fax: 91 40 4900 2999 | Web: www.drreddys.com
